Icon (NASDAQ:ICLR) Director Ronan Martin Murphy Sells 841 Shares of Stock

Icon Plc (NASDAQ:ICLR) Director Ronan Martin Murphy sold 841 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total transaction of $138,167.89. Following the sale, the director directly owned 3,847 shares in the company, valued at $632,023.63. The trade was a 17.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Trading Up 1.0%

Shares of NASDAQ ICLR opened at $167.17 on Thursday. The firm has a 50 day moving average price of $161.93 and a two-hundred day moving average price of $134.18. The stock has a market cap of $12.80 billion, a P/E ratio of 39.24, a price-to-earnings-growth ratio of 6.86 and a beta of 1.21. Icon Plc has a 52-week low of $66.57 and a 52-week high of $203.91. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, topping analysts’ consensus estimates of $2.55 by $0.01. Icon had a net margin of 3.99% and a return on equity of 8.02%. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. During the same quarter in the previous year, the business earned $3.26 earnings per share. Icon’s revenue was up 2.3% compared to the same quarter last year. As a group, equities analysts forecast that Icon Plc will post 9.57 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ICLR. EFG International AG bought a new position in Icon in the fourth quarter worth approximately $27,000. Abound Financial LLC bought a new stake in shares of Icon during the fourth quarter valued at approximately $54,000. GAMMA Investing LLC increased its holdings in shares of Icon by 21.4% during the second quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock valued at $68,000 after acquiring an additional 69 shares in the last quarter. Johnson Financial Group Inc. acquired a new position in shares of Icon during the third quarter worth approximately $71,000. Finally, Blue Trust Inc. lifted its holdings in shares of Icon by 207.5% in the 1st quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock worth $73,000 after purchasing an additional 444 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Icon’s latest quarterly results modestly exceeded expectations. Adjusted EPS was $2.56 versus the $2.55 consensus, while revenue reached $2.06 billion, above the $2.00 billion estimate. Revenue increased 2.3% year over year, providing evidence of continued demand for its outsourced clinical-research services.
• Positive Sentiment: Analyst sentiment includes several bullish targets. BMO Capital Markets raised its target to $187 and Mizuho increased its target to $190, while William Blair upgraded the stock to “strong buy.” The broader analyst consensus remains “Hold,” with an average target of $170.40. Analyst coverage article
• Neutral Sentiment: Insider selling was widespread but appears largely administrative: CEO Barry Balfe sold 382 shares for about $62,675, CFO Nigel Clerkin sold 2,267 shares for approximately $372,445, and several directors also sold shares. The SEC filings state that the transactions were made to cover tax-withholding obligations tied to vested equity awards. Executives and directors retained shares afterward. Icon CFO insider sale
• Neutral Sentiment: Reported short interest was zero shares, indicating no measurable short-selling pressure or potential short-covering catalyst.
• Negative Sentiment: Despite the quarterly revenue beat, EPS declined from $3.26 in the comparable prior-year period. ICLR also trades at a relatively high valuation, with a price-to-earnings ratio near 39 and a PEG ratio above 6, leaving the stock sensitive to any slowdown in growth or weaker guidance.

Analyst Upgrades and Downgrades

ICLR has been the topic of several recent research reports. Citigroup lifted their target price on Icon from $165.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. Robert W. Baird set a $194.00 price objective on Icon in a research report on Friday, July 31st. Leerink Partners set a $145.00 price objective on Icon in a research note on Thursday, May 28th. Bank of America upped their target price on Icon from $125.00 to $150.00 and gave the company an “underperform” rating in a report on Thursday, June 25th. Finally, UBS Group set a $160.00 target price on shares of Icon in a research report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $170.40.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.